Puma Biotechnology, Inc. (PBYI) stock
Close on Nov 18, 2026Market cap $372.70MP/E 13.9Yield –
Earnings
Puma Biotechnology's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Puma Biotechnology's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 25, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026after the close | $55.10M | +1.1% | $0.11 | $0.15 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 6, 2026after the close | $56.50M | +7.8% | $0.16 | $0.19 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026after the close | $44.80M | -2.6% | -$0.07 | -$0.04 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 26, 2026after the close | $75.50M | +27.7% | $0.26 | $0.29 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025after the close | $54.50M | -32.3% | – | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025after the close | $52.40M | +11.3% | $0.12 | $0.15 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 8, 2025after the close | $46.00M | +5.0% | $0.06 | $0.10 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 27, 2025after the close | $59.10M | -18.1% | $0.39 | $0.43 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 7, 2024after the close | $80.50M | +43.5% | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 1, 2024after the close | $47.10M | -13.7% | -$0.09 | -$0.05 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 2, 2024after the close | $43.80M | -17.0% | -$0.10 | -$0.05 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 29, 2024after the close | $72.20M | +9.9% | $0.26 | $0.31 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 2, 2023after the close | $56.10M | -1.8% | $0.12 | $0.17 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 3, 2023after the close | $54.60M | -8.2% | $0.05 | $0.10 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 4, 2023after the close | $52.80M | +15.5% | $0.03 | $0.09 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 2, 2023after the close | $65.70M | +18.6% | -$0.12 | -$0.07 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 3, 2022after the close | $57.10M | +23.6% | -$0.01 | $0.05 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 4, 2022after the close | $59.50M | – | $0.21 | $0.28 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 5, 2022after the close | $45.70M | – | -$0.08 | -$0.01 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 3, 2022after the close | $55.40M | – | $0.10 | $0.21 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 4, 2021after the close | $46.20M | – | -$1.09 | -$0.99 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 5, 2021after the close | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 6, 2021after the close | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 25, 2021after the close | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020after the close | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Puma Biotechnology's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Net Product Revenue | Q4 FY2026 | $56.00M – $58.00M | – | New | Nov 5, 2026 |
| Gross to Net Adjustment | Q4 FY2026 | 28% – 29% | – | New | Nov 5, 2026 |
| Net Income* | Q4 FY2026 | $10.00M – $12.00M | – | New | Nov 5, 2026 |
| Net Product Revenue | FY2026 | $206.00M – $208.00M | – | New | Nov 5, 2026 |
| Total Revenue | FY2026 | $224.00M – $231.00M | $0 | Raised | Aug 6, 2026 |
| Gross to Net Adjustment | FY2026 | 27.5% – 28% | – | New | Nov 5, 2026 |
| Gross to Net Adjustment | FY2026 | 26.5% – 27.5% | 27.5% – 28.5% | Lowered | Aug 6, 2026 |
| Net Income | FY2026 | $17.00M – $20.00M | – | Lowered | Aug 6, 2026 |
| Net Income* | FY2026 | $20.00M – $22.00M | – | New | Nov 5, 2026 |
| Net Income/(Loss)* | FY2026 | $10.00M – $13.00M | – | New | Feb 26, 2026 |
| Net Product Revenue | FY2026 | $205.00M – $209.00M | – | Raised | Aug 6, 2026 |
| Royalty Revenue | FY2026 | $19.00M – $22.00M | – | Lowered | Aug 6, 2026 |
Guidance vs results
The last range Puma Biotechnology gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| Q3 FY2026 | Revenue | $56.00M – $59.00M | $55.10M | Below range |
| Q2 FY2026 | Revenue | $50.00M – $52.00M | $56.50M | Above range |
| Q1 FY2026 | Revenue | $36.00M – $39.00M | $44.80M | Above range |
| Q3 FY2025 | Revenue | $46.00M – $48.00M | $54.50M | Above range |
| Q1 FY2025 | Revenue | $41.00M – $43.00M | $46.00M | Above range |
| Q3 FY2024 | Revenue | $50.00M – $53.00M | $80.50M | Above range |
| Q2 FY2024 | Revenue | $43.00M – $45.00M | $47.10M | Above range |
| Q1 FY2024 | Revenue | $38.00M – $40.00M | $43.80M | Above range |
| Q4 FY2023 | Revenue | $56.00M – $59.00M | $72.20M | Above range |
| Q3 FY2023 | Revenue | $51.00M – $53.00M | $56.10M | Above range |
| Q2 FY2023 | Revenue | $47.00M – $50.00M | $54.60M | Above range |
| Q1 FY2023 | Revenue | $43.00M – $46.00M | $52.80M | Above range |
Guidance history
Every forecast Puma Biotechnology put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 5, 2026 | Gross to Net Adjustment | Q4 FY2026 | 28% – 29% | New |
| Nov 5, 2026 | Net Income* | Q4 FY2026 | $10.00M – $12.00M | New |
| Nov 5, 2026 | Gross to Net Adjustment | FY2026 | 27.5% – 28% | New |
| Nov 5, 2026 | Net Income* | FY2026 | $20.00M – $22.00M | New |
| Nov 5, 2026 | Net Product Revenue | Q4 FY2026 | $56.00M – $58.00M | New |
| Nov 5, 2026 | Royalty Revenue | Q4 FY2026 | $11.00M – $12.00M | Lowered |
| Nov 5, 2026 | Total Revenue | Q4 FY2026 | $67.00M – $70.00M | Raised |
| Nov 5, 2026 | Net Product Revenue | FY2026 | $206.00M – $208.00M | New |
| Nov 5, 2026 | Royalty Revenue | FY2026 | $18.00M – $19.00M | Lowered |
| Nov 5, 2026 | Total Revenue | FY2026 | $224.00M – $227.00M | Raised |
| Aug 6, 2026 | Gross to Net Adjustment | FY2026 | 26.5% – 27.5% | Lowered |
| Aug 6, 2026 | Net Product Revenue | FY2026 | $205.00M – $209.00M | Raised |
| Aug 6, 2026 | Royalty Revenue | FY2026 | $19.00M – $22.00M | Lowered |
| Aug 6, 2026 | Net Income | FY2026 | $17.00M – $20.00M | Lowered |
| Aug 6, 2026 | Gross to Net Adjustment | Q3 FY2026 | 26% – 27% | New |
| Aug 6, 2026 | Net Product Revenue | Q3 FY2026 | $54.00M – $56.00M | New |
| Aug 6, 2026 | Royalty Revenue | Q3 FY2026 | $2.00M – $3.00M | Lowered |
| Aug 6, 2026 | Net Income | Q3 FY2026 | $2.00M – $3.50M | Raised |
| Aug 6, 2026 | Total Revenue | FY2026 | $224.00M – $231.00M | Raised |
| Aug 6, 2026 | Total Revenue | Q3 FY2026 | $56.00M – $59.00M | New |
| May 7, 2026 | Gross to Net Adjustment | Q2 FY2026 | 27% – 28% | New |
| May 7, 2026 | Net Income* | Q2 FY2026 | $2.00M – $4.00M | New |
| May 7, 2026 | License Revenue | FY2026 | $0 | Lowered |
| May 7, 2026 | Net Product Revenue | Q2 FY2026 | $50.00M – $52.00M | New |
| May 7, 2026 | Royalty Revenue | Q2 FY2026 | $2.00M – $3.00M | Lowered |
| May 7, 2026 | License Revenue | Q2 FY2026 | $0 | Lowered |
| May 7, 2026 | Total Revenue | Q2 FY2026 | $52.00M – $55.00M | Raised |
| Feb 26, 2026 | Gross to Net Adjustment | FY2026 | 27.5% – 28.5% | New |
| Feb 26, 2026 | Net Income/(Loss)* | FY2026 | $10.00M – $13.00M | New |
| Feb 26, 2026 | Gross to Net Adjustment | Q1 FY2026 | 29.5% – 30.5% | New |
| Feb 26, 2026 | Net Income/(Loss)* | Q1 FY2026 | -$10.00M – -$8.00M | New |
| Feb 26, 2026 | Net Product Revenue | FY2026 | $194.00M – $198.00M | New |
| Feb 26, 2026 | Royalty Revenue | FY2026 | $20.00M – $23.00M | Lowered |
| Feb 26, 2026 | License Revenue | FY2026 | $0 | Lowered |
| Feb 26, 2026 | Total Revenue | FY2026 | $214.00M – $221.00M | Raised |
| Feb 26, 2026 | Net Product Revenue | Q1 FY2026 | $36.00M – $39.00M | New |
| Feb 26, 2026 | Royalty Revenue | Q1 FY2026 | $2.00M – $3.00M | Lowered |
| Feb 26, 2026 | License Revenue | Q1 FY2026 | $0 | Lowered |
| Feb 26, 2026 | Total Revenue | Q1 FY2026 | $38.00M – $42.00M | Raised |
| Aug 7, 2025 | Gross to Net Adjustment | Q3 FY2025 | 22.5% – 23.5% | New |
| Aug 7, 2025 | Net Income/(Loss)* | Q3 FY2025 | $2.00M – $4.00M | New |
| Aug 7, 2025 | Gross to Net Adjustment | FY2025 | 21.5% – 22% | Raised |
| Aug 7, 2025 | Net Income/(Loss)* | FY2025 | $23.00M – $28.00M | Reaffirmed |
| Aug 7, 2025 | Net Product Revenue | Q3 FY2025 | $46.00M – $48.00M | New |
| Aug 7, 2025 | Royalty Revenue | Q3 FY2025 | $2.00M – $3.00M | Lowered |
| Aug 7, 2025 | License Revenue | Q3 FY2025 | $0 | Lowered |
| Aug 7, 2025 | Total Revenue | Q3 FY2025 | $48.00M – $51.00M | Raised |
| Aug 7, 2025 | Net Product Revenue | FY2025 | $192.00M – $198.00M | Raised |
| Aug 7, 2025 | Royalty Revenue | FY2025 | $20.00M – $24.00M | Lowered |
| Aug 7, 2025 | License Revenue | FY2025 | $0 | Lowered |
| Aug 7, 2025 | Total Revenue | FY2025 | $212.00M – $222.00M | Raised |
| Feb 27, 2025 | Gross to Net Adjustment | Q1 FY2025 | 22.5% – 23.5% | New |
| Feb 27, 2025 | Net Income/(Loss)* | Q1 FY2025 | -$2.00M – $0 | New |
| Feb 27, 2025 | Gross to Net Adjustment | FY2025 | 20.5% – 21.5% | New |
| Feb 27, 2025 | Net Income/(Loss)* | FY2025 | $23.00M – $28.00M | New |
| Feb 27, 2025 | Net Product Revenue | Q1 FY2025 | $41.00M – $43.00M | New |
| Feb 27, 2025 | Royalty Revenue | Q1 FY2025 | $1.50M – $2.50M | Lowered |
| Feb 27, 2025 | License Revenue | Q1 FY2025 | $0 | Lowered |
| Feb 27, 2025 | Net Product Revenue | FY2025 | $192.00M – $198.00M | New |
| Feb 27, 2025 | Royalty Revenue | FY2025 | $20.00M – $24.00M | Lowered |
| Feb 27, 2025 | License Revenue | FY2025 | $0 | Lowered |
| Aug 1, 2024 | Gross to Net Adjustment | Q3 FY2024 | 18.5% – 19.5% | New |
| Aug 1, 2024 | Net Income | Q3 FY2024 | $11.00M – $13.00M | New |
| Aug 1, 2024 | Gross to Net Adjustment | FY2024 | 21% – 22% | Lowered |
| Aug 1, 2024 | Net Income | FY2024 | $12.00M – $15.00M | Reaffirmed |
| Aug 1, 2024 | Net Product Revenue | Q3 FY2024 | $50.00M – $53.00M | New |
| Aug 1, 2024 | Royalty Revenue | Q3 FY2024 | $20.00M – $22.00M | Lowered |
| Aug 1, 2024 | License Revenue | Q3 FY2024 | $0 | Lowered |
| Aug 1, 2024 | Net Product Revenue | FY2024 | $183.00M – $190.00M | Raised |
| Aug 1, 2024 | Royalty Revenue | FY2024 | $30.00M – $33.00M | Lowered |
| Aug 1, 2024 | License Revenue | FY2024 | $1.00M – $2.00M | Lowered |
| May 2, 2024 | Gross to Net Adjustment | Q2 FY2024 | 22% – 23% | New |
| May 2, 2024 | Net Income/(Loss) | Q2 FY2024 | -$9.00M – -$6.00M | New |
| May 2, 2024 | Gross to Net Adjustment | FY2024 | 21.5% – 22.5% | Reaffirmed |
| May 2, 2024 | Net Income/(Loss) | FY2024 | $12.00M – $15.00M | Reaffirmed |
| May 2, 2024 | Net Product Revenue | Q2 FY2024 | $43.00M – $45.00M | New |
| May 2, 2024 | Royalty Revenue | Q2 FY2024 | $2.50M – $3.00M | Lowered |
| May 2, 2024 | License Revenue | Q2 FY2024 | $0 | Lowered |
| May 2, 2024 | Net Product Revenue | FY2024 | $183.00M – $190.00M | Raised |
| May 2, 2024 | Royalty Revenue | FY2024 | $30.00M – $33.00M | Lowered |
| May 2, 2024 | License Revenue | FY2024 | $1.00M – $2.00M | Lowered |
| Feb 29, 2024 | Gross to Net Adjustment | Q1 FY2024 | 23% – 24% | New |
| Feb 29, 2024 | Net Income/(Loss) | Q1 FY2024 | -$12.00M – -$10.00M | New |
| Feb 29, 2024 | Gross to Net Adjustment | FY2024 | 21.5% – 22.5% | New |
| Feb 29, 2024 | Net Income/(Loss) | FY2024 | $12.00M – $15.00M | New |
| Feb 29, 2024 | Net Product Revenue | Q1 FY2024 | $38.00M – $40.00M | New |
| Feb 29, 2024 | Royalty Revenue | Q1 FY2024 | $2.50M – $3.00M | Lowered |
| Feb 29, 2024 | License Revenue | Q1 FY2024 | $0 | Lowered |
| Feb 29, 2024 | Net Product Revenue | FY2024 | $183.00M – $190.00M | New |
| Feb 29, 2024 | Royalty Revenue | FY2024 | $30.00M – $33.00M | Lowered |
| Feb 29, 2024 | License Revenue | FY2024 | $1.00M – $2.00M | Lowered |
| Nov 2, 2023 | Gross to Net Adjustment | Q4 FY2023 | 15.5% – 16.5% | New |
| Nov 2, 2023 | Net Income | Q4 FY2023 | $13.00M – $16.00M | New |
| Nov 2, 2023 | Gross to Net Adjustment | FY2023 | 17.5% – 18% | Lowered |
| Nov 2, 2023 | Net Income | FY2023 | $22.00M – $25.00M | Raised |
| Nov 2, 2023 | Product Revenue, Net | Q4 FY2023 | $56.00M – $59.00M | New |
| Nov 2, 2023 | Royalty Revenue | Q4 FY2023 | $16.00M – $19.00M | Lowered |
| Nov 2, 2023 | Product Revenue, Net | FY2023 | $206.00M – $209.00M | Raised |
| Nov 2, 2023 | Royalty Revenue | FY2023 | $30.00M – $32.00M | Lowered |
| Aug 3, 2023 | Gross to Net Adjustment | Q3 FY2023 | 17.5% – 18.5% | New |
| Aug 3, 2023 | Net Income | Q3 FY2023 | $3.00M – $4.00M | New |
| Aug 3, 2023 | Gross to Net Adjustment | FY2023 | 19% – 20% | Reaffirmed |
| Aug 3, 2023 | Net Income | FY2023 | $20.00M – $24.00M | Reaffirmed |
| Aug 3, 2023 | Product Revenue, Net | Q3 FY2023 | $51.00M – $53.00M | New |
| Aug 3, 2023 | Royalty Revenue | Q3 FY2023 | $3.00M – $5.00M | Lowered |
| Aug 3, 2023 | Product Revenue, Net | FY2023 | $205.00M – $210.00M | Raised |
| Aug 3, 2023 | Royalty Revenue | FY2023 | $25.00M – $30.00M | Lowered |
| May 4, 2023 | Gross to Net Adjustment | Q2 FY2023 | 20% – 21% | New |
| May 4, 2023 | Net Income/(Loss) | Q2 FY2023 | $0 – $1.50M | New |
| May 4, 2023 | Gross to Net Adjustment | FY2023 | 19% – 20% | Reaffirmed |
| May 4, 2023 | Net Income/(Loss) | FY2023 | $20.00M – $24.00M | Reaffirmed |
| May 4, 2023 | Net Product Revenue | Q2 FY2023 | $47.00M – $50.00M | New |
| May 4, 2023 | Royalty Revenue | Q2 FY2023 | $2.00M – $3.00M | Lowered |
| May 4, 2023 | Net Product Revenue | FY2023 | $205.00M – $210.00M | Raised |
| May 4, 2023 | Royalty Revenue | FY2023 | $25.00M – $30.00M | Lowered |
| Mar 2, 2023 | Gross to Net Adjustment | Q1 FY2023 | 21% – 21.5% | New |
| Mar 2, 2023 | Net Income/(Loss) | Q1 FY2023 | -$5.00M – -$2.00M | New |
| Mar 2, 2023 | Gross to Net Adjustment | FY2023 | 19% – 20% | New |
| Mar 2, 2023 | Net Income/(Loss) | FY2023 | $20.00M – $24.00M | New |
| Mar 2, 2023 | Net Product Revenue | Q1 FY2023 | $43.00M – $46.00M | New |
| Mar 2, 2023 | Royalty Revenue | Q1 FY2023 | $4.00M – $6.00M | Lowered |
| Mar 2, 2023 | Net Product Revenue | FY2023 | $205.00M – $210.00M | New |
| Mar 2, 2023 | Royalty Revenue | FY2023 | $25.00M – $30.00M | Lowered |
| Nov 3, 2022 | Gross to net adjustment | FY2022 | 18% – 19% | New |
| Nov 3, 2022 | Royalties | FY2022 | $25.00M – $27.00M | New |
| Nov 3, 2022 | Net income | FY2022 | $7.00M – $9.00M | Lowered |
| Nov 3, 2022 | Product sales, net | FY2022 | $194.00M – $196.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Puma Biotechnology filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Update
- Results
- Results
See a number that looks wrong?